3 active not recruiting, 3 terminated, 2 withdrawn, 1 completed. 10 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 3, Terminated 3, Withdrawn 2, Completed 1, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 2, Unknown 1 |
Follow TNO155: new trials by email Literature Review of TNO155 trials Research Report on TNO155
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants TNO155 - Renal Impairment | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2025-03-19 | 2024-02-29 | |
| Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants TNO155 - Hepatic Impairment | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2025-03-06 | 2024-02-29 | |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Dabrafenib, LTT462, Trametinib - BRAF V600 Colorectal Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2020-07-22 | 2025-12-24 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) MRTX849, TNO155 - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Mirati Therapeutics Inc. | 86 | 2020-04-07 | 2025-04-04 |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Sotorasib, Trametinib, RMC-4630 - Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation | Phase 1 | Active not recruiting | Amgen | 610 | 2019-12-17 | 2025-10-22 |
| Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies TNO155, Spartalizumab, Ribociclib - Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2019-07-30 | 2025-09-30 |
| Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors TNO155, TNO155 in combination with EGF816 (nazartinib) - Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC | Phase 1 | Terminated | Novartis Pharmaceuticals | 227 | 2017-05-26 | 2026-07-09 |
Colorectal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (3) · Colonic Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Lung Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Gastrointestinal Stromal Tumors (1) · Melanoma (1) · Neoplasms (1) · Noonan Syndrome (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Rectal Neoplasms (1) · Recurrence (1)
Novartis Pharmaceuticals (7) · Amgen (1) · Massachusetts General Hospital (1) · Mirati Therapeutics Inc. (1)
United States (7) · Spain (6) · Belgium (5) · Canada (5) · Japan (5) · Australia (4) · Germany (4) · Italy (4) · Netherlands (4) · Singapore (4) · South Korea (4) · China (3) · Taiwan (3) · Denmark (2) · France (2)
2023 (2), 2025 (1)